March 18, 2013 13:30 ET

Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019

NEW YORK, NY--(Marketwire - Mar 18, 2013) - cites in its newly published "Therapeutic Drug Monitoring" report that therapeutic drug monitoring (TDM) will spike to $2.69 billion by 2019. For more information, visit:

Therapeutic drug monitoring can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global therapeutic drug monitoring market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.

The "Therapeutic Drug Monitoring" report covers:

  • Chemiluminescence
  • High Pressure Liquid Chromatography (HPLC)
  • Gas Chromatography/Mass Spectrometry
  • Liquid Chromatography/Mass Spectrometry
  • Flucytosine
  • Triazoles
  • Itraconazole
  • Voriconazole
  • Posaconazole
  • Enzyme Immunoassays
  • Enzyme Multiplied Immunoassay Technique
  • Cloned Enzyme Donor Immunoassays
  • Radio Immunoassays
  • Fluorescence Polarization Immunoassays
  • Lateral Flow Immunoassays
  • Particle Enhanced Turbidimetric Inhibition Immunoassays
  • Affinity Chrome Mediated Immunoassays

The "Therapeutic Drug Monitoring" report examines companies manufacturing therapeutic drug monitoring equipment and supplies in the world. Companies covered include: Abaxis, Abbott, Alere, Alfa Wassermann, AMS, Beckman Coulter, BioMerieux, Carolina Chemistries, DiaSorin, Grifols, Horiba, Medica, Nova Biomedical, Ortho Clinical Diagnostics, Polymedico, Randox, Roche and Siemens.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit:

About is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information